STAT6 modulators and uses thereof
Inventors
Bregman, Howard • Yeoman, John • Downing, Jennifer • REZNIK, SAMUEL K. • Sickmier, Ernest Allen • Cianchetta, Giovanni • Vaswani, Rishi G. • Bifulco, Neil • Tian, Xia • Tasker, Andrew • Hodous, Brian
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure relates generally to STAT6 modulators and uses thereof, and more specifically to compounds, salts, and compositions thereof useful for treating conditions associated with STAT6.
Core Innovation
The disclosed subject matter provides compounds of Formula (I), or pharmaceutically acceptable salts thereof, comprising phosphonic acid derivatives, prodrugs, and intermediate metabolites as STAT6 modulators. These compounds incorporate a core structure featuring a substituted benzo[b]thiophene moiety coupled to an azaspirocyclic or pyrrolopyrrolazocine scaffold. Variable substituents encompass fluorinated phosphonates, phosphonamidates, phosphondiamidates, and ProTide-type amino acid ester prodrugs.
The characterized compounds exhibit selective STAT6 inhibition, cellular pSTAT6 inhibition, and STAT6 SH2-domain binding. The disclosure evaluates effects on interleukin-4- and interleukin-13-induced TARC and CD23 expression, Th2 cellular function, and prodrug conversion profiles. Because background sections are absent from the provided content, the specific technical problem being solved is not explicitly described in patent.
Claims Coverage
The provided claims identify 16 independent claims, comprising genus claim 1 and individually recited compound claims 26–40, spanning two primary inventive features.
Formula (I) compounds and pharmaceutically acceptable salts
Claim 1 covers a compound of Formula (I), or a pharmaceutically acceptable salt thereof, with defined substituent alternatives for R1a, R1b, R2, R3, R4, R5, RP, RP1, and RP2. The defined alternatives encompass hydrogen, halogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, alkoxy, N-linked amino acid, and N-linked amino acid ester groups under specified substitution limits.
Individually recited compounds
Independent claims 26–40 each cover an individually recited compound having the specified chemical structure, or a pharmaceutically acceptable salt thereof.
The claims cover a defined genus of Formula (I) compounds, individually recited chemical species, and their pharmaceutically acceptable salts, with dependent claims defining structural selections and a pharmaceutical composition comprising a claimed compound or salt and a pharmaceutically acceptable excipient.
Stated Advantages
The text describes selective STAT6 inhibition and cellular pSTAT6 inhibition.
The text identifies potential oral bioavailability for the prodrugs.
The text describes effects on IL-4- and IL-13-induced TARC and CD23 expression and on Th2 function.
Documented Applications
A pharmaceutical composition comprising a claimed compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
Treatment of STAT6-responsive inflammatory, autoimmune, allergic, and skin disorders, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and chronic obstructive pulmonary disease.
Treatment of STAT-associated conditions, including cancer and inflammatory disease.
Interested in licensing this patent?